United Kingdom· GB-APID-41327311000001107
Lunsumio 1mg/1ml concentrate for solution for infusion vials
A mosunetuzumab product containing mosunetuzumab, registered in United Kingdom by Roche Products Ltd. The same ATC class is registered in 12 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Mosunetuzumab is registered in 12 of 19 countries.
Countries holding a registration under ATC L01FX25 (mosunetuzumab), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 7 of them publish a price we can compare per daily dose
Mosunetuzumab · ATC L01FX25
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Mosunetuzumab
- Manufacturer
- Roche Products Ltd
- Country
- United Kingdom (GB)
- ATC code
- L01FX25
- ATC class
- Mosunetuzumab
- Defined daily dose
- 1.8 mg, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 2
- gtin07613326052122
- gtin7613326052122
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mosunetuzumab in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainLUNSUMIO 1 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONRoche Registration Gmbh
- United StatesLunsumioGenentech, Inc.
- FinlandLunsumioRoche Registration GmbH
- CzechiaLUNSUMIORoche Registration GmbH, Grenzach-Wyhlen
- BelgiumLunsumio 1 mgRoche Registration
- IcelandLunsumioRoche Registration GmbH*
- Japanモスネツズマブ（遺伝子組換え）中外製薬
- NetherlandsLunsumio 1 mg concentraat voor oplossing voor infusieRoche Registration GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Lunsumio
- Liechtenstein · Lunsumio
- Norway · Lunsumio
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ce07ef60-decb-4b1f-8107-461f7f84aede GET /v1/drugs/ce07ef60-decb-4b1f-8107-461f7f84aede?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "41327311000001107",
"desc": "Lunsumio 1mg/1ml concentrate for solution for infusion vials (Roche Products Ltd)",
"form": "Solution for infusion",
"vpid": "41341511000001109",
"source": "dmd",
"vtm_id": "41332711000001107",
"strength": "1 mg",
"substance": "Mosunetuzumab",
"ingredient": "Mosunetuzumab",
"supplier_code": "2085201000001100"
}See everything about mosunetuzumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.